Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment: Clinical and Translational Oncology

A. Bonaventura, F. Grossi, F. Carbone, A. Vecchié, S. Minetti, N. Bardi, E. Elia, A.M. Ansaldo, D. Ferrara, E. Rijavec, M.G. Dal Bello, G. Rossi, F. Biello, M. Tagliamento, A. Alama, S. Coco, P. Spallarossa, F. Dallegri, C. Genova, F. Montecucco

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1603-1610
Number of pages8
JournalClin. Transl. Oncol.
Volume22
Issue number9
DOIs
Publication statusPublished - 2020

Keywords

  • Immunotherapy
  • Lung cancer
  • Neutrophils
  • Nivolumab
  • NSCLC
  • Resistin
  • biological marker
  • C reactive protein
  • myeloperoxidase
  • neutrophil collagenase
  • nivolumab
  • resistin
  • stromal cell derived factor 1
  • adult
  • aged
  • albumin blood level
  • Article
  • biochemistry
  • blood sampling
  • cell invasion assay
  • cohort analysis
  • controlled study
  • creatinine blood level
  • enzyme linked immunosorbent assay
  • estimated glomerular filtration rate
  • female
  • fibrinogen blood level
  • hematology
  • histology
  • human
  • human tissue
  • immunotherapy
  • leukocyte count
  • lymphocyte count
  • major clinical study
  • male
  • mean platelet volume
  • neutrophil count
  • neutrophil lymphocyte ratio
  • non small cell lung cancer
  • overall survival
  • pilot study
  • platelet count
  • prevalence
  • prospective study
  • receiver operating characteristic
  • systolic blood pressure
  • uric acid blood level

Cite this